Clinical Trials Plenary Session
| Event Time: | Tuesday May 7, 2019 9:15 am to 11:30 am |
| Topic(s): | Aging, Dementia, Cognitive, and Behavioral Neurology, MS and CNS Inflammatory Disease, General Neurology, Headache, Neuromuscular and Clinical Neurophysiology (EMG), Autoimmune Neurology, Neuro-oncology, Neuro Trauma, Critical Care, and Sports Neurology |
| Director(s): | Deborah Hall MD, PhD, FAAN, Holly Hinson MD, MCR, FAAN |
| Description: | This session covers important clinical topics identified from other society meetings that affect patient care. The latest updates within several clinical trials conducted over the course of the last year will be presented. |
| Completion Message: | |
| CME Credits: | 2.25 |
| Core Competencies: |
| Start/End Time | Title | Faculty |
|---|---|---|
| 9:15 AM - 9:30 AM | SPRINT MIND: Results Update and Future Directions | Jeff D. Williamson |
| 9:30 AM - 9:45 AM | Randomized Controlled Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder | Bruce A. C. Cree MD, PhD, MCR, FAAN |
| 9:45 AM - 10:00 AM | Intravenous Immunoglobulin to prevent Myasthenic Crisis after Thymectomy and other Surgical Procedures can be omitted: A Randomized, Controlled, Double-Blind Trial | Josep Gamez MD, PhD |
| 10:00 AM - 10:15 AM | rAAV2/2-ND4 for the Treatment of LHON: 72-week Data from the REVERSE Phase III Clinical Trial | Mark L. Moster MD, FAAN |
| 10:15 AM - 10:30 AM | A Placebo-Controlled Study of Galcanezumab in Patients with Episodic Cluster Headache: Results from the 8-Week Double-Blind Treatment Phase | David W. Dodick MD, FAAN |
| 10:30 AM - 10:45 AM | Use of Tranexamic Acid in Patients with Traumatic Brain Injury: Results from the North American Multi-Center Prehospital TXA for TBI Trial | Susan Rowell MD, MCR |
| 10:45 AM - 11:00 AM | From Bench to Bedside to Beam: Hippocampal-sparing during Brain Irradiation | Vinai Gondi |
| Speaker | Disclosure |
|---|---|
| Bruce A. C. Cree, MD, PhD, MCR, FAAN | Dr. Cree has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Personal compensation for consulting from Abbvie, Akili, Alexion, Biogen, EMD Serono and Novartis.. |
| David W. Dodick, MD, FAAN | Dr. Dodick has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr. Dodick reports personal fees from Acorda, Amgen, Alder, Allergan, Autonomic Technologies, Biohaven, Colucid, Eli Lilly, eNeura, Foresight Capital, Neurolief, Zosano, WL Gore, Vedanta Associates, Promius Pharma, Magellan Healthcare, CC West Ford Group, Nocira, Novartis, NuPathe, Supernus, Electrocore, Tonix, Teva, Alcobra, Insys, Ipsen, Charleston Laboratories, Biocentric, Theranica, Xenon. ZP Opco. Travel expense reimbursement and speaking fee from Sun Pharma. Anticipated income from consulting within next 3 weeks not previously reported: Impel pharmaceuticals (currently under review by Mayo Clinic Medical Industry Relations Committee). Compensation for activities related to data safety monitoring committee from Axsome. Speaking fees, or fees related to CME content development: Healthlogix, Medicom Worldwide, Medlogix Communications, MedNet, Miller Medical Communications, PeerView Operation Services America, Web MD/Medscape, American Academy of Neurology, American Headache Society, PeerView Institute for Medical Education, Chameleon Communications, Academy for Continued Healthcare Learning, Universal Meeting Management, Haymarket Medical Education, Global Scientific Communications, UpToDate, Meeting LogiX. Consulting use agreement through employer: NeuroAssessment Systems, Myndshft. Dr. Dodick has received compensation for serving on the Board of Directors of Board of Directors position: King-Devick Technologies, Ontologics. Dr. Dodick holds stock and/or stock options in Hold equity in: Aural Analytics, Healint, Theranica, Second Opinion/Mobile Health, Epien, which sponsored research in which Dr. Dodick was involved as an investigator. Dr. Dodick holds stock and/or stock options in Hold equity in: Aural Analytics, Healint, Theranica, Second Opinion/Mobile Health, and Epien. |
| Josep Gamez, MD, PhD | Dr. Gamez has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Minoryx, Italfarmaco, Octapharma AG, and CSL Behring. |
| Mark L. Moster, MD, FAAN | Dr. Moster has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Gensight and Sanofi Genzyme. Dr. Moster has received research support from GenSight. |
| Jeff D. Williamson | Dr. Williamson has nothing to disclose. |